Clinical trials: Molluscum Contagiosum
- Condition Molluscum Contagiosum
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Molluscum Contagiosum
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.
- Trial name
- NCT03436615
- Testing
- SB206 4%, SB206 8%, SB206 12%
- Where
- 18 sites in United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Novan, Inc.
Molluscum Contagiosum
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC.
- Trial name
- B-SIMPLE2 (NCT03927703)
- Testing
- SB206 12%
- Where
- 27 sites in United States
- Volunteers
- 355 people
- Sponsor
- Novan, Inc.
Molluscum Contagiosum
A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 850 subjects 6 months of age and older with molluscum contagiosum (MC).
- Trial name
- B-SIMPLE4 (NCT04535531)
- Testing
- SB206 10.3% berdazimer, vehicle gel
- Where
- 55 sites in United States
- Volunteers
- 891 people
- Sponsor
- Novan, Inc.
Molluscum Contagiosum
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC.
- Trial name
- NCT03927716
- Testing
- SB206 12%
- Where
- 35 sites in United States
- Volunteers
- 352 people
- Sponsor
- Novan, Inc.
Molluscum Contagiosum
Cantharidin Application in Molluscum Patients-1
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum.
- Trial name
- CAMP-1 (NCT03377790)
- Testing
- VP-102 - Cantharidin, Topical Film Forming Solution
- Where
- 18 sites in United States
- Volunteers
- 266 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Molluscum Contagiosum
Cantharidin Application in Molluscum Patients
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum.
- Trial name
- CAMP-2 (NCT03377803)
- Testing
- VP-102 - Cantharidin, Topical Film Forming Solution
- Where
- 15 sites in United States
- Volunteers
- 262 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Molluscum Contagiosum
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution [0.7% (w/v) cantharidin] (VP-102) when…
- Trial name
- NCT03186378
- Testing
- VP-102 with applicator
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Verrica Pharmaceuticals Inc.